|
WO2008116948A1
|
|
Method for preparation of a furanosesterpene of marine origin
|
|
EP1939192A1
|
|
Cyclopentanone derivatives, method of synthesis and uses thereof
|
|
EP1939191A1
|
|
Furan derivatives, method of synthesis and uses thereof
|
|
KR20080075922A
|
|
Dibenzene derivatives as calcium channel blockers
|
|
EP1886990A1
|
|
Phenyl-prenyl-ether derivatives for the treatment of cognitive neurodegenerative or neuronal diseases or disorders
|
|
EP1849785A1
|
|
N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors
|
|
EP1798220A1
|
|
Dibenzene derivatives as calcium channel blockers
|
|
WO2006045581A1
|
|
The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
|
|
EP1772146A1
|
|
Polyunsaturated fatty acids as bace inhibitors
|
|
EP1749552A1
|
|
Use of collismycin and derivatives thereof as oxidative stress inhibitors
|
|
EP1749523A1
|
|
GSK-3 inhibitors
|
|
WO2005123073A1
|
|
Marine compounds with calcium channel blocking properties for the treatment of cognitive or neurodegenerative diseases
|
|
BRPI0510865A
|
|
selective butyrylcholinesterase inhibitors: compound, pharmaceutical composition, use of a compound and process for preparing a compound
|
|
ES2258406A1
|
|
USE OF HETEROCICLIC COMPOUNDS AS NEUROGENIC AGENTS.
|
|
GB0327908D0
|
|
GSK-3 inhibitors isolated from marine organisms
|
|
GB0316094D0
|
|
Acetylcholinesterase dual inhibitors
|
|
GB0223494D0
|
|
Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease
|
